Gilvetmab Product Grant Application Instructions

MERCK Animal Health

Thank you for your interest in applying to the Gilvetmab Product Grant Program. As a reminder, this grant program provides free product (gilvetmab) necessary to complete a proposal objective and does not provide funding.

Below you will find the complete instructions for the content, form, and process of application submission. Your application should be typed according to the guidelines indicated below and converted to a PDF file format.

*****To submit your completed PDF format application, please e-mail the application and all relevant supporting files to GilvetmabGrant@merck.com.*****

Application and Submission Information

Content and Form of Application Submission

It is critical that applicants follow the instructions in the product grant opportunity announcement. Applications that are out of compliance with these instructions may be delayed or not accepted for review.

Non-Responsive Applications

Applications with the following attributes will be deemed non-responsive and will not be reviewed.

- Applications that request active pharmaceutical ingredient (API) for non-clinical applications
- Applications that are purely preclinical in nature
- Applications that do not involve the canine model

MERCK Animal Health

- Applications that involve stage III canine oral melanoma (see Ongoing Clinical Trial link on the Gilvetmab Product Grant Program website for information regarding ongoing clinical trials)

Page Limitations

All page limitations must be followed as described. Applications exceeding specified page limitations will not be considered.

Instructions for Application Submission

The following sections are required for preparing an application to this product grant opportunity. The application should be typed following the page specifications (see below: Page specifications), converted to PDF format, and submitted electronically (see below: Submission of Proposal).

- Cover page (limit 1 page): Title of proposed study; name, affiliation, email, and postal mailing address of all investigators; underline name of investigator to whom product would be shipped; anticipated number of dogs to be treated; anticipated time frame to study completion; estimated cost of study and anticipated sources of funding.
- Project/Performance Site Locations (limit 2 pages): The project/performance site locations should include identification of all locations that will be involved in the planned project, including clinics, reference laboratories used, and animal facilities if applicable.
- Study Objectives/Scientific Hypothesis(es) (limit ¼ page): Concise overview of study objectives and hypothesis(es)
- Research Plan (limit 2 pages): Summary of proposed project including background; study design; reason for numbers of animals needed; expectations for results; methods of analysis.
- Timeline (limit 1 page): Provide a timeline denoting key dates and activities necessary to complete the research. A maximum of 24 months from the time of receipt of product is allowed for each research project.
- References (limit 1 page): Pertinent related literature references
- Budget (limit 1 page): Outline expected expenditures
- Current and Pending Support (no page limit): Include a list of any current and pending sources of funding and/or additional grants requested for this project. Product will not

be shipped until proof of adequate funding to complete the research proposal is supplied.

- **Biographical sketch (limit 2 pages each):** List all key personnel and explain their role on the proposed project.
- **Client consent form (limit 1 page):** Copy of proposed client consent form

Page specifications

Single-spaced, 12-point font, 1" margins, printable on 8.5" x 11" pages; applications exceeding specified page limitations will not be considered

Supplementary Required Documentation

In addition to the application, supplementary required documentation includes:

- Proof of adequate funding to cover projected expenses
    - Proof is not required at the time of application submission, but will be required prior to shipping of product to accepted proposals. Proof must be provided within 12 months of proposal acceptance.
- Proof of approval from all relevant and required organizations (i.e. scientific governing bodies, IACUC, etc.) The study should be approved by an Institutional Animal Care and Use Committee (IACUC) and documentation of this approval (or pending approval) must be provided in the event product is awarded. If there is no applicable IACUC approval process available, a signed statement assuring humane treatment of veterinary patients will be requested.

Submission Deadlines and Application Cap

Final deadlines for submission of the complete application package can be found for the relevant application cycle on the Gilvetmab Product Grant program webpage.

Applicants are encouraged to submit applications well before the due date, as each application cycle will be capped at a maximum of 25 applications that will be reviewed. Applications exceeding the cap will be automatically rolled over into the next application cycle unless otherwise noted.

Merck Animal Health reserves the right to modify or discontinue the program at any time without notice. All Merck Animal Health decisions relating to the Program are final.

MERCK Animal Health